Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Obstet Gynecol Reprod Biol. 2013 Oct;170(2):464-7. doi: 10.1016/j.ejogrb.2013.06.041. Epub 2013 Jul 31.

Results of oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent ovarian granulosa cell tumors.

Author information

1
Department of Surgery, Institut Gustave Roussy and University Paris Sud, Villejuif, France. Electronic address: sebastien.gouy@igr.fr.

Abstract

OBJECTIVES:

To assess the efficacy and morbidity of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) for relapsed ovarian granulosa cell tumors (OGCT).

STUDY DESIGN:

Between 2007 and 2009, patients with relapsed OGCT who had been treated with HIPEC after CRS in our institution were retrospectively analyzed.

RESULTS:

We identified 7 patients who had undergone CRS plus HIPEC. Macroscopically complete cytoreduction had been performed in all patients. The location of the recurrence was exclusively the pelvis in 2 cases and both the pelvis and abdomen in 5 cases. We had administered an intraperitoneal perfusion of oxaliplatin (460 mg/m(2)) or oxaliplatin (360 mg/m(2)) plus irinotecan (360 mg/m(2)) heated up to 41-43°C for 30 min. No post-operative mortality nor any grade IV morbidity (according to the Clavien and Dindo classification) had occurred. One lymphocyst (grade III) had appeared which had twice required percutaneous drainage. Six patients had experienced extra-abdominal complications (all grade II). Median follow-up after CRS plus HIPEC was 32 months (range, 25-56). Among the 7 patients, 2 are disease free, 3 had relapsed with peritoneal carcinomatosis and 2 had relapsed with liver metastases.

CONCLUSIONS:

HIPEC (using oxaliplatin or oxaliplatin plus irinotecan) should not be recommended to treat relapsed OGCT.

KEYWORDS:

Hyperthermic intraperitoneal; Ovarian granulosa cell tumors; Recurrence; Surgery

PMID:
23915762
DOI:
10.1016/j.ejogrb.2013.06.041
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center